Nascent Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018	2017 - 2012
Revenue	0	1	0.75	0	0	Upgrade
Revenue Growth (YoY)	-	33.33%	-	-	-	Upgrade
Gross Profit	0	1	0.75	0	0	Upgrade
Selling, General & Admin	1.49	0.93	1.83	3.15	1.11	Upgrade
Research & Development	0.27	0.2	0.32	0.29	0.25	Upgrade
Other Operating Expenses	1.5	0.33	-0	0	0	Upgrade
Operating Expenses	2.14	1.46	2.15	3.45	1.37	Upgrade
Operating Income	-2.16	-0.46	-1.4	-3.45	-1.37	Upgrade
Interest Income	0	0	0	0	0	Upgrade
Interest Expense	1.72	0.34	0.34	0.09	0	Upgrade
Other Expense / Income	-3.29	-0.32	-0.78	0.47	0	Upgrade
Pretax Income	-2.8	-0.47	-0.96	-4	-1.37	Upgrade
Income Tax	2.21	-0.32	0.36	0.09	-0	Upgrade
Net Income	-2.8	-0.15	-1.31	-4.09	-1.37	Upgrade
Shares Outstanding (Basic)	119	108	72	34	30	Upgrade
Shares Outstanding (Diluted)	119	108	72	34	30	Upgrade
Shares Change	10.05%	48.93%	110.34%	14.30%	16.25%	Upgrade
EPS (Basic)	-0.02	-0.00	-0.02	-0.12	-0.05	Upgrade
EPS (Diluted)	-0.02	-0.00	-0.02	-0.12	-0.05	Upgrade
Free Cash Flow	-1.79	0.41	-0.99	-0.55	-0.71	Upgrade
Free Cash Flow Per Share	-0.02	0.00	-0.01	-0.02	-0.02	Upgrade
Gross Margin	-	100.00%	100.00%	-	-	Upgrade
Operating Margin	-	-45.71%	-186.72%	-	-	Upgrade
Profit Margin	-	-14.77%	-175.31%	-	-	Upgrade
Free Cash Flow Margin	-	41.35%	-131.57%	-	-	Upgrade
EBITDA	-2.16	-0.61	-1.42	-3.45	-1.37	Upgrade
EBITDA Margin	-	-60.82%	-189.35%	-	-	Upgrade
Depreciation & Amortization	1.34	0	0	0	0	Upgrade
EBIT	-3.5	-	-	-	-	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.